Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bio Medica Laboratories's change in inventory for the quarter that ended in Mar. 2025 was ₹-107.7 Mil. It means Bio Medica Laboratories's inventory
increased by ₹107.7 Mil
from Mar. 2024 to Mar. 2025 .
Bio Medica Laboratories's change in inventory for the fiscal year that ended in Mar. 2025 was ₹-107.7 Mil. It means Bio Medica Laboratories's inventory
increased by ₹107.7 Mil
from Mar. 2024 to Mar. 2025 .
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Bio Medica Laboratories's Days Inventory for the quarter that ended in Mar. 2025 was 114.83.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Bio Medica Laboratories's Inventory Turnover for the quarter that ended in Mar. 2025 was 1.59.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Bio Medica Laboratories's Inventory-to-Revenue for the quarter that ended in Mar. 2025 was 0.33.
3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Bio Medica Laboratories's Inventory to Revenue for the quarter that ended in Mar. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio Medica Laboratories Change In Inventory Related Terms
Bio Medica Laboratories Change In Inventory Historical Data
* Premium members only.
The historical data trend for Bio Medica Laboratories's Change In Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio Medica Laboratories Change In Inventory Calculation
Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.
For stock reported annually, GuruFocus uses latest annual data as the TTM data. Change In Inventory for the trailing twelve months (TTM) ended in Mar. 2025 was ₹-107.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Change In Inventory of ₹-107.7 Mil mean?
Bio Medica Laboratories (NSE:BMLL) has a Change In Inventory of ₹-107.7 Mil as of Mar. 2025. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Bio Medica Laboratories and its competitors.
Is Bio Medica Laboratories' Change In Inventory too high?
Bio Medica Laboratories' current Change In Inventory is ₹-107.7 Mil. Overall, Bio Medica Laboratories has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Bio Medica Laboratories' Change In Inventory compare to ISRG and BDX?
Bio Medica Laboratories' Change In Inventory of ₹-107.7 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Medical Devices & Instruments company?
A good Change In Inventory depends on the Medical Devices & Instruments industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Bio Medica Laboratories and its competitors. Bio Medica Laboratories's current Change In Inventory is ₹-107.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio Medica Laboratories stock overvalued right now?
Bio Medica Laboratories (NSE:BMLL) has a current Change In Inventory of ₹-107.7 Mil. The current Change In Inventory is ₹-107.7 Mil. Bio Medica Laboratories' overall GF Score™ is 18/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For Bio Medica Laboratories (NSE:BMLL), the current Change In Inventory is ₹-107.7 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bio Medica Laboratories Ltd is engaged in the manufacturing of Pharmaceutical Parenteral Formulations. It manufactures generic drugs in the form of injectables namely Liquid Injections and Dry Powder Injections. These injectables are available in both single dose and multi dose forms, catering both human and veterinary needs. Its products address a wide range of medical needs and preferences. The majority of revenue is derived from the sales of Liquid injections. Geographically, it operates predominantly in India, and internationally, it exports to Afghanistan.
18GF Score
Get the complete analysis for NSE:BMLL
Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BMLL has been successfully added to your 
